Trimetazydyna jako leczenie uzupełniające – pacjent z chorobą niedokrwienną serca i przewlekłą niewydolnością serca Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2012
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Cacko, A. (2012). Trimetazydyna jako leczenie uzupełniające – pacjent z chorobą niedokrwienną serca i przewlekłą niewydolnością serca . Medycyna Faktów , 5(3(16), 40-44. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2453
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ochotny R.: Cytoprotekcja w leczeniu choroby wieńcowej. Znaczenie leków o modyfikowanym uwalnianiu. Folia Cardiol. 2003; 10(1): 1-8.
2. Kantor P.F., Lucien A., Kozak R. et al.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000 Mar 17; 86(5): 580-8.
3. Charakterystyka produktu leczniczego. Centrum Informacji o Leku [online].
4. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012 Jul; 33(14): 1787-847. Epub 2012 May 19.
5. Brottier L., Barat J.L., Combe C. et al.: Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur. Heart J. 1990 Mar; 11(3): 207-12.
6. Gunes Y., Guntekin U., Tuncer M. et al.: Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009 Jul; 24(4): 277-82. Epub 2009 Jul 22.
7. Belardinelli R., Lacalaprice F., Faccenda E. et al.: Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur. J. Cardiovasc. Prev. Rehabil. 2008 Oct; 15(5): 533-40.
8. Marazzi G., Gebara O., Vitale C. et al.: Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv. Ther. 2009 Apr; 26(4): 455-61. Epub 2009 Apr 24.
9. Zhang L., Lu Y., Jiang H. et al.: Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J. Am. Coll. Cardiol. 2012 Mar 6; 59(10): 913-22.
2. Kantor P.F., Lucien A., Kozak R. et al.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000 Mar 17; 86(5): 580-8.
3. Charakterystyka produktu leczniczego. Centrum Informacji o Leku [online].
4. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012 Jul; 33(14): 1787-847. Epub 2012 May 19.
5. Brottier L., Barat J.L., Combe C. et al.: Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur. Heart J. 1990 Mar; 11(3): 207-12.
6. Gunes Y., Guntekin U., Tuncer M. et al.: Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009 Jul; 24(4): 277-82. Epub 2009 Jul 22.
7. Belardinelli R., Lacalaprice F., Faccenda E. et al.: Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur. J. Cardiovasc. Prev. Rehabil. 2008 Oct; 15(5): 533-40.
8. Marazzi G., Gebara O., Vitale C. et al.: Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv. Ther. 2009 Apr; 26(4): 455-61. Epub 2009 Apr 24.
9. Zhang L., Lu Y., Jiang H. et al.: Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J. Am. Coll. Cardiol. 2012 Mar 6; 59(10): 913-22.